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Non-traumatic subarachnoid haemorrhage (SAH) is a neurosurgical emergency that may present similarly to a benign headache, yet poses high morbidity and
mortality in what often times are young and otherwise healthy patients. While the diagnosis may be made via several different modalities, not all of these are available
to every emergency physician. A high suspicion for SAH along with a good history and physical examination may best serve patients in these resource-limited settings.
Adequate resuscitative and supportive care, combined with prompt transfer to a facility with neurosurgical capabilities is integral to optimizing patient outcomes.L’he´morragie sous-arachnoı¨dienne (HSA) non traumatique est une urgence neurochirurgicale que l’on peut aise´ment confondre avec une me´ninge´e be´nigne, mais qui
est pourtant associe´e a` de forts taux de morbidite´ et de mortalite´ chez des patients souvent jeunes et ge´ne´ralement en bonne sante´. S’il est possible d’e´tablir un diagnostic
en suivant diffe´rentes modalite´s, celles-ci ne sont pas toutes a` la disposition de tous les me´decins urgentistes. De forts soupc¸ons de HSA associe´s a` un bon examen
des ante´ce´dents et un bon examen physique constituent probablement la meilleure option pour les patients dans ces contextes caracte´rise´s par des ressources limite´es.
Des soins de re´animation et de maintien, suivis d’un transfert rapide vers une structure dote´e d’un service de neurochirurgie, sont essentiels pour optimiser l’e´tat de
sante´ des patients.African relevance
 There is a dearth of epidemiologic research on the inci-
dence, mortality, and economic impact of subarachnoid
haemorrhage (SAH) in Africa.
 Diagnosis and management of SAH is challenging in
resource-limited settings and requires less reliance on neuro-
imaging and early efforts for transfer to an institution with
neurosurgical care.
 Several areas of controversy including seizure prophylaxis,
blood pressure control, and antiﬁbrinolytic therapy are
aspects of management to discuss with the accepting physi-
cian at a transferring institution if possible.Introduction and importance to Africa
Subarachnoid haemorrhage (SAH) can be secondary to
trauma or due to non-traumatic, aneurysmal disease. The lat-
ter will be discussed exclusively here.
An idea of the basic incidence and mortality of SAH in
Africa can be gleaned from the small, country-speciﬁc articles
that are available. For example, in a recent Kenyan autopsy
study, 2.1% of 134 deaths were due to subarachnoid haemor-
rhage and in a Nigerian stroke registry, 11.3% of strokes over
a two year period were due to subarachnoid haemorrhage.
1,2
One study fromMorocco suggests that the incidence or at least
the detection of aneurysmal disease is rapidly increasing with 2
patients identiﬁed to have cerebral aneurysm in 1983 to 24
patients in 1999 at a specialty hospital.
3
The outcome of
patients diagnosed with SAH was found in one study to vary
little by geography and depends more on neurological grade,
patient age, and amount of SAH rather than any treatment
variations. This study examined data from 3567 patients
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variation in outcome based on geography. However, the only
African country included in this study was South Africa.
4
Another major difference in the clinical evaluation of SAH
speciﬁc to African countries is the relative shortage of com-
puted tomography (CT) scanners available to clinicians as
compared to other clinical settings. Without CT scanners,
healthcare providers must rely on history, physical exam,
and lumbar puncture to make the diagnosis of SAH.
Between 1% and 4% of patients with headache reporting to
the emergency centre in low to middle income countries are
ultimately diagnosed with subarachnoid haemorrhage.5
Between 3% and 26% of patients with SAH die prior to reach-
ing the hospital and those who do arrive alive have a high like-
lihood of rapid deterioration and mortality rate of up to 33%.
6
Therefore, considering SAH in the differential diagnosis of
every headache patient and having the knowledge to recognize
when it is appropriate to initiate the diagnostic evaluation for
SAH are important clinical skills for every emergency physician.
Patients with SAH that are initially misdiagnosed have
been found to appear clinically well as opposed to their coun-
terparts with SAH and altered level of consciousness, focal
motor deﬁcit, or have a severe headache with classically
abrupt onset during exertion who are much more likely to
be correctly diagnosed on initial presentation. The most com-
mon alternate diagnoses that patients are ultimately found to
have SAH are initially given are: headache of unknown cause,
migraine/cluster/tension headache, or meningitis/encephalitis.
Jonathan Edlow MD asserts that the misdiagnosis of SAH
stems from three recurring patterns of error, ‘‘failure to
appreciate the spectrum of clinical presentation, failure to
understand the limitations of computed tomography (CT),
and failure to perform and correctly interpret the results of
lumbar puncture.’’
7
Pathophysiology
Subarachnoid haemorrhage is a type of stroke in which bleed-
ing occurs in the subarachnoid space alone or in conjunction
with bleeding elsewhere in the central nervous system. The
haemorrhage is classiﬁed as either primary (non-traumatic)
or secondary (traumatic). This is a clinically important distinc-
tion as treatment options and prognosis differ with the speciﬁc
aetiology of the haemorrhage. Approximately 75% of SAH
are primary and, of those, 74% are due to a ruptured aneu-
rysm. Twenty percent of patients with one aneurysm will have
a second. A non-traumatic aetiology of SAH, based either on
history or aneurysmal distribution pattern on head CT
requires further imaging, such as CT Angiography (CTA), to
identify aneurysms that may be amenable to surgical or endo-
vascular intervention. The majority of non-traumatic SAH
without an aneurysm are idiopathic while a minority are due
to more rare conditions including arteriovenous malforma-
tions (AVM), cerebral artery dissection, coagulopathies,
moyamoya syndrome, mycotic aneurysms, neoplasms, pitui-
tary apoplexy, vasculopathies, or use of sympathomimetic
drugs, such as cocaine, methamphetamine or phenylephrine.
8
The deleterious effects of SAH include direct damage to the
brain by the haemorrhage and resultant mass effect as well as
the inﬂammatory cascade it triggers. Cerebral blood ﬂow
and autoregulation are reduced, resulting in global brainischaemia. This leads to increased intracranial pressure
(ICP), decreased cerebral perfusion pressure (CPP), and the
continued propagation of the inﬂammatory cascade resulting
in increased permeability of the blood brain barrier.
9
History
Subarachnoid haemorrhage can occur in any age group, but its
highest incidence is amongst those aged 40 to 60 years old and
it occurs in a 3:2 female to male ratio.
10
Multiple international
studies have identiﬁed hypertension, cigarette smoking, alco-
holism, and cocaine use as risk factors for SAH.
11
Patients with
a history of prior aneurysmal haemorrhage have a 1–2% risk
of recurrence per year.
12
Up to 20–50% of patients have a
warning headache in the days or weeks before presenting with
acute SAH. This is sometimes called a ‘‘sentinel headache’’ or
‘‘sentinel bleed’’ and is, as the name implies, thought to be due
to a relatively small bleed from the offending aneurysm that
warns of a more catastrophic haemorrhage to come. In these
patients, the goal is to make the diagnosis and intervene
before the catastrophic bleed occurs. It is important to ask
patients about family history since 2% of patients with a ﬁrst
degree relative with a history of an aneurysm will develop the
disease themselves. This risk is even greater if multiple family
members have been diagnosed with an aneurysm or if there
is a family of autosomal dominant polycystic kidney disease
(ADPKD).13
Physical exam
Physical exam ﬁndings may vary widely with one study dem-
onstrating most patients with SAH arriving to the emergency
centre with a GCS of 15 (55%) and a Hunt and Hess score
of less than 3 (35%).
15
Providers should keep in mind that as
cited above, most patients with SAH will present awake and
alert. See below for Hunt and Hess scoring. In any patient with
headache, abnormal level of consciousness, or vomiting the
physician should strongly consider the possibility of SAH. In
the presence of high-risk features (Table 1), improvement in
symptoms alone, spontaneously or in response to treatment,
should not dissuade the physician from continuing to pursue
the diagnosis of SAH.
In the unconscious patient, ocular haemorrhages may be
the only physical exam ﬁnding indicating SAH as a cause of
the altered level of consciousness. These ocular haemorrhages
may be ﬂame-shaped, subhyaloid, or vitreous and are thought
to be due to venous obstruction from increased intracranial
pressure in SAH.16Excluding SAH with clinical decision rules
Perry et al. enrolled close to 2000 patients over ﬁve years in
Canada to identify high risk characteristics of patients to
develop a clinical decision rule to exclude patients from further
work-up for SAH. They developed three different rules for
adult patients with non-traumatic headaches whose intensity
peaked within an hour of onset or were associated with syn-
cope. The most applicable version of their clinical rules for
Africa is the only one that does not include arrival by ambu-
lance (Table 2).
Table 1 Risk factors for and clinical characteristics of SAH. SAH subarachnoid haemorrhage.
14
Sudden, severe headache that reaches maximal intensity in seconds to minutes after onset
Acute headache after exertion (i.e. sex, exercise, heavy lifting)
Prior history of SAH or aneurysm
Family history of SAH, Ehlers–Danlos Type IV, ADPKD, aortic coarctation, or Marfan’s syndrome
Severe hypertension
Previous vascular injuries/malformations involving extracranial vessels
Young, middle-aged patients (40–60 years old)
Table 2 Perry et al. clinical decision rule.
17
Investigate patients for subarachnoid haemorrhage further if one or
more variables present
1. Age > 40
2. Complaint of neck pain or stiﬀness
3. Witnessed loss of consciousness
4. Onset with exertion
Figure 1 An example of the classic ‘‘starman’’ of subarachnoid
blood that can be seen on a non-contrast head CT. This scan also
shows early hydrocephalus with dilation of the temporal horns of
the lateral ventricles, which can be present even after the acute
SAH blood becomes isodense and is no longer distinguishable
from brain tissue. Photo courtesy: Alex Koyfman, MD.
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28.4–28.8% speciﬁcity. An external validation of this rule
resulted in a sensitivity of 97.1% for exclusion of SAH and
it is therefore likely a useful tool to help identify patients with
sudden, severe headache who require no further work-up
(including head CT) for SAH in resource challenged
environments.18
Diagnosis of SAH and the importance of timing
Delineating the time of onset of symptoms is critically impor-
tant in the diagnosis of SAH. As discussed in the sections
below, the sensitivity of head CT in SAH is more sensitive
early in a patient’s course and degrades rapidly the farther
away from symptom onset. This is in contrast to the detection
of xanthochromia, which is usually not detected until 12 h
after symptom onset. While it may be difﬁcult in patients with
altered mental status or severe headache to nail down the exact
moment of symptom onset, it is critical in judging the sensitiv-
ity and speciﬁcity of the diagnostic tests discussed below.
Laboratory studies
Laboratory studies in general, add little to the diagnosis of
SAH. Their main role is to exclude other causes of serious
headache including pre-eclampsia with proteinuria and a posi-
tive urine pregnancy test, meningitis or intracranial abscess
which may have a leukocytosis on complete blood count, or
cocaine-induced intracranial haemorrhage which may be seen
on urine drug screen. Once the diagnosis of SAH is made,
there are electrolyte derangements such as hypernatremia
and hyperglycaemia that are common in SAH and their man-
agement is discussed later.
Radiology studies
A non-contrast head CT is an accepted routine part of
the work-up of SAH (Figure 1), when available, but retrospec-
tive reviews have suggested 9% of SAH would be missed if the
diagnostic algorithm relied on head CT alone. The diagnosticaccuracy of CT can be affected by a number of factors
including the patient’s haematocrit, the time from the onset
of symptoms to the acquisition of the CT images, the technical
speciﬁcations of the scanner, and the skill of the person inter-
preting the scan.
19
A conservative estimate is that a patient’s
serum haematocrit needs to be at least 30% to distinguish
blood from cortex on head CT (though some authors argue
that this distinction can be made at levels as low as 27%).20
Images obtained from ﬁfth generation CT scanners, com-
pleted within 6 h of symptom onset, and interpreted by a neu-
roradiologist have been reported to have 100% sensitivity for
detection of SAH. Sensitivity drops to 85.7% in patients whose
scans were done greater than 6 h after symptom onset as eryth-
rocytes dissipate and lyse to an extent that it is difﬁcult to dis-
tinguish them from the surrounding brain tissue after this time
point.
21
The sensitivity of 100% for head CT performed within
6 h was validated at an additional facility over a 7-year period,
but the investigators excluded SAH patients who presented
without headache.22 The interpreting radiologist also plays
an important role in the sensitivity of CT. Scans read in
non-tertiary centres by non-neuroradiologists carry a lower
negative predictive value and, in one study in the Netherlands,
13% of CT scans read as negative in the local community were
overread at a tertiary centre as positive or inconclusive for
SAH. This decreased sensitivity based on the interpreting
Figure 2 A clearly positive lumbar puncture performed on a
patient with several days of apoplectic headache, a head CT only
signiﬁcant for mild early hydrocephalus, and a CTA positive for
aneurysmal SAH. Photo courtesy of Michael Runyon, MD.
Subarachnoid haemorrhage 143radiologist is especially important to consider in African hos-
pitals that do not have access to a neuroradiologist.23 This sen-
sitivity of CT scans obtained within 6 h has been contested by
a retrospective case-control study that found a sensitivity of
only 80%, with 11 of 55 subarachnoid haemorrhages detected
to have negative head CTs and positive lumbar punctures.24 It
has been argued that this study by Mark et al. was limited in its
retrospective nature, inclusion of patients with clear cranial
nerve deﬁcits, and mixture of both neuroradiologists and gen-
eral radiologists interpreting the head CTs.25
For this reason, in the patient with a negative head CT or in
facilities where head CT is unavailable, the patient should
undergo lumbar puncture, except in cases noted above (symp-
tom onset less than six hours with ﬁfth generation CT scanner,
and interpreted by a neuroradiologist) looking for the sequelae
of haemorrhage in the subarachnoid space in the form of either
red blood cells (RBCs) or their breakdown products of biliru-
bin and oxyhaemoglobin expressed as xanthochromia.26
However, there is debate about which patients need neuro-
imaging prior to lumbar puncture. The concern is that lumbar
puncture may precipitate brain herniation in patients with ele-
vated intracranial pressure due to a mass lesion. The published
research is conﬂicting, but in general the patients at highest risk
for deterioration after LP are those with impaired conscious-
ness, a focal neurologic deﬁcit, or clinical features of increased
ICP. In the absence of any of these features, it is probably safe
to proceed directly to LP when CT is not available.
27–30
It has been a conventional teaching that visualizing venous
pulsations ensures a normal ICP and that it is safe to perform
a lumbar puncture in the absence of neuroimaging. To our
knowledge, there is no study that conﬁrms or denies this teach-
ing. One study used advanced ophthalmologic techniques to
compare central retinal vein pressures and ICP and found a
direct correlation between the two although this study did
not examine venous pulsations directly, but extrapolated in
their conclusions that increased pressures would eradicate
venous pulsations.31 However, there are case reports of
patients with documented venous pulsations found to have
increased ICPs on lumbar puncture although none had acute
neurologic changes after the procedure suggesting any hernia-
tion suggesting the presence of venous pulsations may still be
an indicator of safety for lumbar puncture rather than an indi-
cator of a normal ICP.32
The American College of Emergency Physicians (ACEP)
has a clinical policy statement that endorses the use of lumbar
puncture if head CT is an unavailable resource. This policy
states, ‘‘When subarachnoid haemorrhage is suspected, it is
appropriate to perform a head CT and if negative, proceed
to LP. If head CT is not readily available, selected patients
may have diagnosis and care expedited with performance of
an LP ﬁrst. These patients should have no signs of increased
intracranial pressure and no focal neurologic ﬁndings. In cases
of negative LP and negative CT and high suspicion of aneu-
rysm or AVM, other neuroimaging studies or consultation
may be appropriate.’’
Unfortunately, the diagnostic challenge does not end with
the decision whether or not to obtain a head CT prior to lum-
bar puncture as the interpretation of CSF studies is not always
straightforward. When performing a lumbar puncture to eval-
uate for SAH, one is looking speciﬁcally for the sequelae of
bleeding in the subarachnoid space manifested by either xan-
thochromia or red blood cells (Figure 2). Xanthochromia isthe yellowing of CSF as a result of bilirubin from the break-
down of erythrocytes and this enzyme-dependent process
may take up to 12 h. Pink tinged CSF due to released haemo-
globin from lysed red blood cells is detectable several hours
sooner (See Table 3).
The reference standard for detecting xanthochromia is CSF
spectrophotometry. However, most laboratories use simple
gross inspection of the CSF looking for xanthochromia, which
is much less sensitive and can miss the diagnosis in up to half
of specimens when compared to spectrophotometry.33,34 How-
ever, at least one study found a 100% sensitivity for detecting
xanthochromia in CSF by clinicians, which may suggest that in
resource-challenged settings xanthochromia may be excluded
based on gross visual inspection alone. This same study found
that if clinicians were unsure of the colour of CSF, describing
it as ‘‘doubtful’’ than spectrophotometry was required to accu-
rately exclude the presence of xanthochromia.35 Xanthochro-
mia itself, is not speciﬁc for SAH as it is also seen in clinical
situations where CSF protein levels are high for other reasons
such as various infections, inﬂammatory conditions, or trau-
matic taps that have >100,000 RBCs introduced into the sub-
arachnoid space.36
The absence of red blood cells in clear CSF effectively
excludes subarachnoid haemorrhage. When red blood cells
are present in the CSF in the absence of xanthochromia, there
are two primary possibilities: either the patient has a subarach-
noid haemorrhage and there has been insufﬁcient time from
the onset of bleeding to allow for the development of xantho-
chromia or the CSF has been contaminated by red blood cells
as a result of injury induced by the procedure itself (a
‘‘traumatic tap’’). The provider’s impression of a traumatic
lumbar puncture is subjective and prone to error.
Investigations of CSF D-dimer assays to differentiate SAH
from a traumatic tap were initially promising, but subse-
quently found to be unhelpful and are not recommended to
differentiate traumatic vs. RBCs from true SAH.37,38
Another method that has traditionally been used to differ-
entiate true SAH from a traumatic tap is to compare the red
blood cell count in the ﬁrst CSF tube to that in the ﬁnal tube.
Indeed, while a decreasing red blood cell count is reassuring,
Table 3 Summaries of the Hunt and Hess Scale, the World Federation of Neurological Surgeons Scale, and the Prognosis on
Admission of Aneurysmal Subarachnoid Hemorrhage Scale.51–55
Grade Hunt and Hess Scale WFNS Scale PAASH Scale
I Asymptomatic, or minimal headache and slight
nuchal rigidity
GCS score 15 GCS score 15
II Moderate to severe headache, nuchal rigidity, no
neurological deﬁcit other than cranial nerve palsy
GCS score 13–14 without focal deﬁcit GCS score 11–14
III Drowsiness, confusion, or mild focal deﬁcit GCS score 13–14 with focal deﬁcit GCS score 8–10
IV Stupor, moderate to severe hemiparesis, possibly
early decerebrate rigidity, and vegetative
disturbances
GCS score 7–12 GCS score 4–7
V Deep coma, decerebrate rigidity, moribund
appearance
GCS score 3–6 GCS score 3
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gle absolute or percent decrease in CSF red blood cell count in
subsequent specimen tubes has proved reliable for excluding
the diagnosis of SAH.39 A recent small retrospective study
however may provide some guidance. Gorchynski et al. retro-
spectively looked at 305 patients with RBCs present in their
CSF and found a negative predictive value of 100% for
SAH on CT when the RBC count was less than 500 in the
fourth CSF tube and a corresponding positive predictive value
of 100% when the RBC count was greater than 10,000 in the
fourth CSF tube.40 A more recent and larger case series of
close to 5000 patients who underwent lumbar puncture over
an eight year period also found that the RBC count in the
fourth tube was helpful in risk stratifying patients for SAH.
This study found no patient with SAH who had less than
100 RBCs in the fourth tube of CSF while greater than
10,000 RBCs in the fourth tube increased the odds of SAH
by a factor of 6.41 While each study has its own limitations,
these cell counts may help provide some guidance to physicians
practicing in resource-limited settings.
The timing of lumbar puncture is an important factor in
determining the utility of the test for diagnosing SAH. Xan-
thochromia may present as soon as 6 h after symptoms of
headache begin; however, some argue that in a stable patient
it may be reasonable to delay lumbar puncture for 12 h after
symptom onset as sensitivity of the test approaches 100% at
this time. Xanthochromia is still detectable in almost 100%
of patients two weeks after haemorrhage, 70% after three
weeks, and in 40% of patients after one month.42,43
Alternative management strategies include performing an
immediate lumbar puncture and if the tap is non-diagnostic
in a patient with a high risk features for SAH, repeat the pro-
cedure at 12 h after symptom onset to maximize sensitivity and
avoid unnecessary transfers.44
Researchers have also attempted to delineate when it is safe
to forgo CT all together and utilize lumbar puncture alone to
rule out SAH. Schull found that 8–12% of patients complain-
ing of headache with a onset of less than one minute and
normal neurologic exam, normal vital signs including temper-
ature, normal level of consciousness, and no neck stiffness.
Lumbar punctures performed at 12 h after symptom onset in
his patient population were close to 100% sensitive for SAH
when spectrophotometry was performed looking for xantho-
chromia. However, this may not apply to settings with a higher
prevalence of HIV. This high sensitivity of delayed lumbar
puncture may be especially useful in settings with limitedavailability to CT scanners. Schull constructed mathematical
models based on a proposed algorithm of waiting until 12 h
after symptom onset to perform LP the above patient popula-
tion and if negative, to discharge them home effectively having
ruled out the diagnosis of SAH (Figures 3 and 4). Patients with
indeterminate or positive LPs underwent head CT. In this
mathematical model, out of 100 patients who underwent this
‘‘LP ﬁrst’’ model, there would be 79–83 fewer head CTs per-
formed and 7–11 additional LP’s performed. This study had
several limitations including the fact that it was a theoretical
model and has not been part of a clinical trial, but does
provide evidence that a prospective study of this ‘‘LP ﬁrst’’
model may help decrease unnecessary diagnostic radiation
exposure and could prove beneﬁcial in settings where CT
imaging is not accessible.45
In clinical settings where more advanced radiography is
available, CT angiography has been considered as a possibility
for looking directly at the cerebral vasculature for an aneu-
rysm. CTA consistently has 100% sensitivity for larger aneu-
rysms, but this drops off and is as low as 92% in aneurysms
less than 4 mm.46,47 It is important to note that approximately
2% of the population will have an asymptomatic cerebral
aneurysm detectable on CT angiography.48 The main question
at the time of evaluation is not whether the patient has an
aneurysm, but whether they have subarachnoid haemorrhage.
Detection of an incidental aneurysm puts the patient at risk for
potentially unnecessary interventions such as aneurysmal coil-
ing or clipping and the potential complications of those inter-
ventions. The CTA itself also increases the risk of malignancy
secondary to radiation exposure and renal injury from the
nephrotoxic effects of contrast.49 There is also a signiﬁcant
psychological burden placed on a patient if he or she knows
they have a cerebral aneurysm which may unnecessarily
increase anxiety surrounding any future headaches or head
trauma. Another risk of moving towards CTA as a primary
diagnostic tool in SAH is the concept of ‘‘technology creep’’
or the skills of physicians as diagnosticians will be lost to
increasing rates of radiographic imaging in patient work ups.50
Management
Once the diagnosis of SAH has been made, grading the sever-
ity of the bleed and clinical condition of the patient via one of
the numerous clinical grading systems facilitates communica-
tion of the patient’s clinical status and likely prognosis between
physicians and provides a reproducible method of ongoing
Figure 3 Possible diagnostic algorithm for SAH in resource limited ED where non-contrast head CT is available. AMS = altered mental
status, CT = computed tomography, CTA= computed tomography angiography, LP = lumbar puncture, LOC = level of conscious-
ness, NSG= neurosurgery, SAH= subarachnoid haemorrhage, Tx = transfer. aRefer to Tables 1 and 2. bUnilaterally dilated pupil,
hypertension with bradycardia, persistent vomiting.
Subarachnoid haemorrhage 145monitoring for clinical deterioration. Several different scales
have been developed including the Hunt and Hess Scale,51
Glasgow Coma Scale,52 Fisher Scale,53 Prognosis on Admis-
sion of Aneurysmal Subarachnoid Haemorrhage (PAASH)54
and World Federation of Neurological Surgeons Scale
(WFNS)55 The Hunt and Hess Scale and WFNS are among
the most commonly used. In a cohort of 50 patients with con-
ﬁrmed SAH, the interobserver variability was found to be
highest in the Hunt and Hess scoring system and lowest in
the WFNS and PAASH scales.56 In a previous study of 537
patients with SAH, the prognostic value of the WFNS and
PAASH were compared with PAASH being slightly favoured
as its odds ratio for poor outcome at three months increased
more gradually than that of the WFNS.57
While the optimal end points for blood pressure manage-
ment remain controversial, there is some evidence that
re-bleeding is more common in patients with a systolic blood
pressure of greater than 160 mmHg and this complication
worsens the overall prognosis.58 Ideal agents to control a
patient’s blood pressure in SAH include nicardipine, labetalol,
and esmolol, rather than the non-selective vasodilators
nitroprusside or hydralazine which can theoretically increase ICP.
Ischaemia due to vasospasm is a main threat to patients
surviving the initial SAH. While the pathophysiology of vaso-
spasm is not completely understood, it manifests as delayed
cerebral ischaemia (DCI) and is radiographically apparent5–15 days after the initial SAH. Nimodipine is a calcium chan-
nel antagonist that is predominantly a cerebrovascular dilator
shown to have a long-lasting effect when applied topically or
systemically and is thus far the only known agent with proven
beneﬁt against DCI.59
A 2008 literature review published in Stroke reconﬁrmed
these ﬁndings and recommended oral nimodipine 60 mg every
4 h for three weeks as standard treatment of aneurysmal sub-
arachnoid haemorrhage. It is still unclear what role, if any,
other calcium channel blockers or those given by IV route have
in the management of SAH for the prevention of vasospasm.60
Oral nimodipine 60 mg every four hours is now a Class I rec-
ommendation for all patients diagnosed with SAH.
Magnesium sulphate has also been recently investigated as
an agent to help decrease the incidence and severity of vaso-
spasm and subsequent ischaemic disease in SAH. In a 2010
study in Germany, 107 patients with known SAH were ran-
domized to either placebo or a bolus and drip of magnesium
with serum target concentration of 2–2.5 mmol/L magnesium
for up to 10 days followed by 12 days of oral therapy. The
incidence of DCI was found to be lower in the magnesium
vs. placebo group (22% vs. 51%) as measured by serial CT.
Vasospasm was also lower in the magnesium group vs. placebo
(67% vs. 85%).61 However, a larger phase III study random-
ized 1204 patients to either magnesium or placebo for 20 days
and found a lack of clinical beneﬁt, even when subgroups were
Figure 4 Possible diagnostic algorithm for SAH in resource limited ED where non-contrast head CT is not available. AMS = altered
mental status, CT = computed tomography, CTA = computed tomography angiography, LP = lumbar puncture, LOC = level of
consciousness, NSG = neurosurgery, SAH= subarachnoid haemorrhage, Tx = transfer. aRefer to Tables 1 and 2.
146 K.L. Modisett et al.examined. This second study calls into question the utility of
magnesium for preventing vasospasm in SAH.62
In addition to delayed ischaemia, re-bleeding is also a lead-
ing cause of morbidity and mortality in patients who initially
survive SAH. Antiﬁbrinolytic therapy to prevent re-bleeding
in SAH has been studied since 1967, but still does not have a
deﬁnitive role or strong recommendation in SAH treatment.
In general, studies have suggested that the antiﬁbrinolytic
properties of agents such as tranexamic acid (TXA) or epsilon
aminocaproic acid (EACA) may be offset by their detrimental
side effect of cerebral vasospasm with resulting ischaemia.63,64
There may be a role for TXA or EACA in the prevention of
early re-bleeding in SAH if combined with early aneurysmal
treatment such as surgical excision or clipping and prophylac-
tic prevention of cerebral vasospasm concomitantly with these
agents. One randomized prospective study of 505 patients with
SAH did show a reduction in re-bleeding from 10.8% to 2.4%
and an 80% reduction in mortality in patients receiving early
TXA (1 g IV at time of CT diagnosis and then every 6 h until
the aneurysm was occluded) as opposed to control patients
with no apparent increased risk of ischaemic events or clini-
cally signiﬁcant vasospasm.65 The most recent AHA guidelines
offer a level IIa recommendation, ‘‘For patients with an
unavoidable delay in obliteration of aneurysm, a signiﬁcant
risk of re-bleeding, and no compelling medical contraindica-
tions, short-term (<72 h) therapy with tranexamic acid or
aminocaproic acid is reasonable to reduce the risk of early
aneurysm re-bleeding.’’66 More prospective randomized trials
will need to be performed to better elucidate any overall mor-
tality beneﬁt with this therapy and the duration of administra-
tion needed to maximize beneﬁt while also limiting risk of
cerebral ischaemia.
In addition to re-bleeding, hydrocephalus (deﬁned as acute
ventricular enlargement in the ﬁrst 72 h) is another earlycomplication of SAH, which is often associated with intraven-
tricular extension of the bleeding. Hydrocephalus is seen
in roughly 20–30% of SAH patients. The signiﬁcance of
hydrocephalus, is unclear in asymptomatic patients. If patients
are symptomatic or have an altered level of consciousness,
temporary or permanent diversion of cerebrospinal ﬂuid
(CSF) via ventriculostomy or shunt placement is recom-
mended. Another option for the emergent shunting of CSF
in the ED is lumbar puncture. This has the advantage of being
a familiar and accessible procedure for the emergency physi-
cian, but has not been formally studied. The potential down-
side of this approach is that drainage of CSF via lumbar
puncture prior to repair could potentially precipitate aneurysm
rupture. However, it is reasonable to discuss this option with
the consulting neurosurgeon as a potential temporizing mea-
sure in symptomatic patients.
The incidence of seizure and the role of prophylactic anti-
convulsants in the management of SAH have not been well
deﬁned. Most studies looking at the incidence of seizure in
SAH are retrospective and are not always able to clearly con-
ﬁrm the diagnosis of seizure activity since the reported events
often occur in the pre-hospital setting or without EEG conﬁr-
mation. In general, the prophylactic use of anticonvulsants,
such as phenytoin, may be considered in the setting of acute
SAH patient, especially if the patient has a history of prior sei-
zure, but cannot be routinely recommended since the beneﬁts of
treatment are unclear. Some smaller retrospective reviews have
actually reported a worse cognitive outcome at 3 months in
patients loaded with phenytoin and a 23% incidence of adverse
drug reaction secondary to anticonvulsant administration.67–69
Hyponatremia occurs in approximately 10–30% of patients
with SAH and may predict worse clinical outcome. In
uncontrolled prospective studies there was an association
between hyponatremia and excessive natriuresis with volume
Subarachnoid haemorrhage 147contraction, resulting symptomatic vasospasm, and down-
stream ischaemic effects. The natural response would be to
replace this ﬂuid with isotonic IV solutions, yet several studies
have suggested ﬂuid replacement with smaller volumes of
hypertonic solutions such as 3% saline, 5% albumin, or treat-
ment with mineralocorticoids, allow for smaller volume resus-
citation, increased regional cerebral blood ﬂow, increased
brain tissue oxygen, and improved sodium levels vs. isotonic
ﬂuid replacement.70 In general, the ﬂuid status of patients with
SAH needs to be closely monitored with invasive strategies
such as CVP monitoring or daily weights in select patients when
available.71–73
In addition to sodium, glucose control may also impact
long-term outcome in SAH. A systematic literature search on
glycaemic control in patients with SAH found 22 publications.
Although individual studies varied, in general, presentation of
SAH with hyperglycaemia was linked to worse outcome, but
tight glucose control with insulin was associated with an
increased risk of hypoglycaemia, which also was linked to
worse outcome. This review concluded that while hyperglyca-
emia and hypoglycaemia should be avoided in SAH, there is
not a speciﬁc glucose target in the management of SAH that
can be recommended.74
As with any critically ill patient, maintenance of euthermia
will help to decrease the systemic inﬂammatory cascade and so
close temperature monitoring is appropriate in the emergency
department
Ideally, all patients with known or suspected aneurysmal
subarachnoid haemorrhage should have a neurosurgical
consult to help deﬁne the optimal management strategy. This
may involve stabilizing and transferring the patient to an alter-
native institution for deﬁnitive therapy, which is typically
endovascular coiling or surgical clipping of the aneurysm.
Patients with aneurysmal subarachnoid haemorrhage also will
often undergo further diagnostic imaging to rule out a second
aneurysm that has not yet ruptured. Speciﬁc recommendations
from the AHA help guide screening in patient’s asymptomatic
relatives as the odds ratio of having an asymptomatic aneu-
rysm in an individual with a ﬁrst degree relative with aneurysm
is 4.0.75
Disposition
When and where possible, all patients with SAH should be
admitted to a neurosurgical intensive care unit for close
monitoring. If neurosurgical consult is a signiﬁcant distance
from the current facility or the patient is clinically decompen-
sating, consider pre-emptively securing the airway with
endotracheal intubation prior to transfer if a ventilator or
personnel who can manually ventilate throughout transport
and upon arrival to the transferring facility are available.
Also try to ensure that the transporting team has both the
resources and training to closely monitor the patient’s hemo-
dynamic and neurologic status and intervene as indicated in
the case of decompensation.
Conclusion
The exact incidence of SAH in Africa is unknown, but there
is a suggestion it may be increasing in frequency and must
be considered in any patient with a headache. SAH shouldbe ruled out early in the patient’s presentation as it carries
a risk of rapid deterioration and high mortality. Several his-
torical features including sudden severe pain after exertion,
family history, and severe hypertension may aid in making
the diagnosis and a normal neurological exam should not
reassure the physician if the suspicion for SAH is high. If
a patient has a normal head CT, but symptoms began
greater than 6 h prior to the study a lumbar puncture should
be performed to look for evidence of blood in the cerebro-
spinal ﬂuid (CSF). Once the diagnosis of SAH is made,
early arrangement for a facility with neurosurgical capabili-
ties is paramount. Prior to transfer, patients should undergo
standard resuscitation with close monitoring for change in
clinical condition. Blood pressure control, electrolyte moni-
toring, and temperature management are all critical in the
emergency department. Discussions regarding antiﬁbrinolytic
therapy with either tranexamic acid (TXA) or epsilon ami-
nocaproic acid (EACA) as well as seizure prophylaxis with
anti-epileptics and management of hydrocephalus via CSF
drainage should all be mentioned with the accepting neuro-
surgeon. All patients with SAH should be admitted to a
neurosurgical intensive care unit for either endovascular coil-
ing or surgical clipping for deﬁnitive management of the
aneurysm.Conﬂicts of interest
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